Roche announced today the completion of its acquisition of LumiraDx’s Point-of-Care technology, following the necessary antitrust and regulatory approvals. The acquisition will see Roche integrate LumiraDx’s multi-assay point-of-care platform, along with its R&D, operational, and commercial sites, into Roche’s global…
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion on updating the Wegovy® (semaglutide 2.4 mg) label. This update reflects data from the SELECT cardiovascular outcomes…
PROTEINA Co., Ltd., in partnership with Seoul National University (SNU) and Seoul National University Hospital (SNUH), has announced groundbreaking research published in Nature Biomedical Engineering. The study introduces a novel method for personalizing treatment for acute myeloid leukemia (AML) patients…
Verastem Oncology, a biopharmaceutical company focused on developing new cancer treatments, announced its intention to offer and sell shares of common stock and accompanying warrants to purchase common stock. The offering will also include pre-funded warrants, which can be purchased…
Verastem Oncology, a biopharmaceutical company focused on cancer treatments, announced the pricing of an underwritten public offering. The offering includes 13,333,334 shares of common stock and accompanying warrants to purchase up to 13,333,334 shares at $3.00 per share and warrant.…
Bristol Myers Squibb today announced the validation of its near-term and net-zero science-based targets by the Science Based Targets initiative (SBTi) as part of a mid-year update on its environmental initiatives. This milestone underscores the company’s progress in reducing emissions…
Roche announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (Port Delivery System with ranibizumab) for treating diabetic macular edema (DME) and diabetic retinopathy (DR), the leading causes of vision loss in adults with diabetes.…
Roche announced new, four-year data from the RHONE-X extension study today. The study met all primary endpoints, demonstrating that Vabysmo® (faricimab) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years. The…
Roche announced positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist for treating type 2 diabetes and obesity. The data showed that participants with…
Revolution Medicines, a clinical-stage oncology company dedicated to targeting RAS-addicted cancers, has announced the publication of a peer-reviewed research paper in Cancer Discovery. The paper showcases the efficacy of their RAS(ON) multi-selective inhibitor, RMC-7977 (representative of investigational drug RMC-6236), in…
Global pharmaceutical leader Lupin Limited announced today that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Dabhasa, Gujarat. The EIR follows the inspection conducted from…
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company focused on developing and commercializing innovative products, announced a CEO succession plan effective August 1, 2024. Paul R. Edick will retire from his operational and Chairman roles after more than seven…
